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Abstract
The mucosal immune system is unique to the gastrointestinal mucosa, in which a large number of immune cells
are located and exert multiple functions. Meanwhile, ~100 trillion microorganisms are thought to co-inhabit in the
gastrointestinal tract. Furthermore, immune cells and gut microbiota have a mutual influence and the maintenance
of this symbiotic relationship results in gut homeostasis. A recent study suggested that a disturbance of gut
microbiota—so called “dysbiosis”—is related to various diseases, such as inflammatory bowel disease (IBD) and
colitis-associated cancer (CAC). In this review, we discuss the relationship between gut microbiota and the mucosal
immune system with regard to the development of IBD and CAC. In addition, we elucidate the possibility of
probiotics in treatment against these diseases.
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Background
The mammalian gastrointestinal tract, where digestion
and absorption occurs, acts as the frontline of defense
against microorganisms from the environment. There-
fore there is an established unique immune surveillance
system called the mucosal immune system. It is sup-
posed that a half of immunocompetent cells reside in
the gut mucosa, and the balance between them with a
variety of properties, including T helper 17 (Th17) cells
and regulatory T (Treg) cells, is thought to be controlled
exquisitely. Characteristics of the mucosal immune sys-
tem are represented by their contrasted immune func-
tions, such as the removal of pathogens and immune
unresponsiveness to the food antigens and indigenous
gut microbiota. Increasing evidence suggests that the gut
microbiota also plays key roles in homeostatic mainten-
ance of the mucosal immune system. Imbalance of gut
microbiota, so called “dysbiosis”, based on dysregulation
of the mucosal immune system affects the development
and pathogenesis of various diseases such as allergy, dia-
betes, autoimmune diseases and cancer [1, 2]. In
addition, a recent finding has suggested that when feces
of healthy adults were intra-rectally inoculated into pa-
tients with recurrent Clostridium difficile infection, the
symptoms improved in association with the recovery
from dysbiosis [3], which would be a clear example of
gut microbiota contributing to restraint of colonic
inflammation. Furthermore regarding the onset of in-
flammatory bowel disease (IBD) and colitis-associated
cancer (CAC), the interaction between the mucosal im-
mune system and gut microbiota is important, because
in germfree animal models of these diseases, no symp-
toms are observed [4, 5]. In this review, we discuss the
roles of gut microbiota and the mucosal immune system
on the development of IBD and CAC.
Review
Gut microbiota in IBD
IBD is categorized into Crohn’s disease (CD) and ulcera-
tive colitis (UC) based on pathophysiological characteris-
tics. UC is an inflammatory disease confined to the
colonic mucosa, whereas CD has the potential to de-
velop along the entire gastrointestinal tract with a higher
occurrence in the small and large intestines. Because
both diseases exhibit repeated remission and relapse, it
is important that we urgently improve the quality of life
of patients with IBD. In accordance with the develop-
ment of an analytical method, based on bacterial 16S
rDNA and next generation sequencing (NGS), the char-
acteristics of gut microbiota in patients with IBD are
rapidly being elucidated. A loss of bacterial diversity and
dysbiosis is present in the gut microbiota of patients
with IBD, as commonly detected using NGS. In particu-
lar, there is a marked decrease in the occupancy of Fir-
micutes and Bacteroidetes in gut microbiota, which
normally predominates in a healthy adult. It has been
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reported that 46 strains of Clostridium derived from
mice and 17 strains of Clostridium derived from humans
induced differentiation of Foxp3+ Treg cells, resulting in
mass production of IL-10, via augmentation of TGF-β
provided by colonic epithelial cells [6, 7]. It was then
demonstrated that Clostridium butyricum when used as
a probiotic, could induce IL-10 production from macro-
phages in colonic mucosa, which resulted in suppression
of acute colitis in mice [8]. It has been discussed that bu-
tyrate participated in suppression of colitis and colorec-
tal cancer. The bacterial metabolite, butyrate, induces
the differentiation of colonic Foxp3+ Treg cells and ame-
liorates the development of colitis. A possible mechan-
ism for this regulation of differentiation may be that
butyrate enhances histone H3 acetylation in the pro-
moter and conserved, non-coding sequence regions of
the Foxp3 locus [9]. Because the occupancy of Clostrid-
ium clusters IV and XIVa, in which numerous butyrate-
producing bacteria exist, have been shown to be de-
creased in the gut microbiota of patients with IBD, it
would be expected that clinical applications of these re-
sults would follow.
With regard to the interaction of the mucosal immune
system and gut microbiota, secretory immunoglobulin A
(IgA) is important. The presence of secretory IgA in the
intestinal lumen is indispensable for the exclusion of
pathogenic germs and neutralization of toxins. Germ-
free mice have few IgA-producing cells in their intestinal
mucosa. Total bacterial numbers increase markedly in
the mice deleted activation induced cytidine deaminase
(AID) gene, which is normally essential for somatic
hypermutation and class switch recombination during
IgA gene rearrangement. IgA produced in inhibitory re-
ceptor of immune system (programmed cell death-1
(PD-1)) gene-deficient mice had a low affinity for bac-
teria, which caused alterations of microbial communities
in the gut [10]. In addition, it has been recently reported
that some gut microbiota was coated with IgA, and IgA-
coated fecal bacteria taken from patients with IBD exac-
erbated dextran sulfate sodium (DSS)-induced colitis in
gnotobiotic mice [11].
Gut microbiota in colorectal cancer
Colorectal cancer is one of the most common fatal ma-
lignancies in the world. The involvement of gut micro-
biota in the development of colorectal cancer has been
noted for some time. IL-10-deficient mice and TCRβ/
p53 double knockout mice do not develop colorectal
cancer under germfree environment, providing a ration-
ale for the association between colorectal cancer and gut
microbiota [12]. Chronic inflammation is known to pre-
dispose an individual to cancer, and as such, the
presence of IBD increases the risk of colorectal cancer.
Another such example would be CAC. The molecular
mechanisms underlying the pathogenesis of CAC are
unclear and do not follow the adenoma-carcinoma
sequence [13]. It is urgent to clarify the mechanism
underlying development of CAC, because ~20 % of
patients with chronic inflammation in the form of UC
develop CAC within 30 years from the onset, with at
least half of the cases resulting in death. A recent study
demonstrated that dysbiosis of gut micobiota plays a key
role in the pathophysiology of CAC. Bacterial diversity is
remarkably decreased in gut microbiota of sporadic
colorectal cancer and CAC mice models. When gnoto-
biotic mice are colonized with feces taken from sporadic
colorectal cancer or CAC mice, the incidence and num-
ber of tumors are increased in both cases, compared
with those colonized with feces of healthy mice. CAC
can be experimentally induced in rodent models by the
combination of introduction to azoxymethane (AOM)
and repeated exposure to the inflammatory agent DSS.
Results from time-course analysis of the composition of
gut microbiota during development of CAC in this
model indicated tumor-bearing mice showed enrichment
in operational taxonomic units (OTUs) affiliated with
members of the Bacteroides, Odoribacter, and Allobaculum
genera and decreases in OTUs affiliated with members of
the Prevotellaceae and Porphyromonadaceae families.
Furthermore, conventionalization (colonization of germ-
free mice with gut microbiota) with tumor-bearing mice
significantly increased colon tumorigenesis compared
to those colonized with feces of healthy mice [14].
However, mice exposed to the chemical mutagen do
not develop tumors if they receive antibiotics and mice
that received feces of tumor-bearing mice do not de-
velop tumors if they are not exposed to the mutagen.
These findings suggest that gut microbiota plays a part
in the initiation of colorectal cancer. CAC results from
the complex relationship between chronic inflamma-
tion and dysbiosis of gut microbiota, which would
induce irreversible changes to intestinal epithelial cells.
Bacteroides fragilis toxin, produced by enterotoxigenic
B. fragilis (ETBF), triggers colorectal cancer by binding
to colonic epithelial cells and stimulating cleavage of
the cell adhesion molecule E-cadherin, which act as the
tumor suppressor protein [15]. Antibody-mediated
blockade of interleukin-17 (IL-17), a key cytokine for
proinflammatory responses, inhibits ETBF-induced col-
itis and tumor formation [16]. Gut microbiota of IL-10
deficient mice developing spontaneously severe colitis
have decreases in bacterial diversity and increases in
the occupancy of Enterobacteriaceae [17]. IL-10 defi-
cient mice colonized with either Escherichia coli
(E. coli) or Enterococcus faecalis develop colon inflam-
mation, but only the mice receiving E. coli developed
colon tumors. Moreover, it was reported that Colibactin,
the product of polyketide synthase (pks) in E. coli NC101,
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cleaved double stranded DNA in colonic epithelial cells
and promoted invasive carcinoma in AOM-treated IL-
10deficient mice [18]. Because the expression of the
ETBF toxin gene and pks gene of E. coli NC101 is
higher in patients with colorectal cancer when com-
pared to healthy adults, aberrant proliferation of these
bacteria caused by dysbiosis of gut microbiota would
induce disruption of epithelial barrier function and
contribute to the mechanism of CAC development.
However, there is some uncertainty, because the murine
AOM/DSS model administered microbes from patients
with colorectal cancer developed unexpectedly fewer
tumors than those that received bacteria from healthy
human donors [19]. Therefore, we would need to valid-
ate the evidence, accumulated by studies using animal
models of colorectal cancer, in human. Furthermore, it
has also been revealed that the role of gut microbiota in
cancer extended to treatment, influencing not only the
effectiveness of chemotherapy but also its side effects.
Both germfree mice and antibiotic-treated mice show
cyclophosphamide resistance and in these mice, patho-
genic Th17 cells are shown to be decreased [20]. Taken
together, it is likely that modulating the gut microbiota
will become an effective tool to combat colorectal
cancer.
CAC and IL-6/Stat3 pathway
The mucosal activation of the IL-6/signal transducer and
activator of transcription 3 (Stat3) pathway is important
for the pathogenesis of IBD and CAC. The inflammatory
cytokine IL-6 shows multiple functions and modulates
various physiological and immune responses. IL-6 exerts
its biological action by binding to two types of mem-
brane receptors, specifically the IL-6 receptor alpha sub-
unit (IL-6Rα) and gp130. IL-6 binds to IL-6Rα at the cell
membrane of target cells and this complex in turn asso-
ciates with gp130, inducing signal transduction via phos-
phorylation of Stat3. IL-6Rα is expressed on specific
cells, such as neutrophils, macrophages, hepatocytes,
and several lymphocyte subsets, whereas gp130 is
expressed on the cell surface of various cell types.
Through this mechanism, the canonical IL-6 signal can
transmit their signal to limited cells, which express the
IL-6Rα. Suppressor of cytokine signaling 3 (SOCS3) is
IL-6/Stat3 responsive protein which inhibits phosphoryl-
ation of Stat3 by binding to Janus kinase (JAK) and
negatively regulates IL-6-induced signaling. In patients
with CD and in murine models of CD (SAMP1/Yit),
expression of IL-6 and SOCS3 in the gut is enhanced
and Stat3 is excessively phosphorylated [21]. It was also
reported that there is an increase in the serum levels of
soluble form of IL-6Rα (sIL-6Rα) under inflammatory
conditions. sIL-6Rα is produced either by TNFα convert-
ing enzyme (TACE), which proteolytically cleaves
extracellular domain of membrane-bound IL-6Rα, or by
the differential splicing of IL-6Rα mRNA. IL-6 shows an
affinity to sIL-6Rs, forming the IL-6/sIL-6Rα complex
that can interact with gp130 and induce IL-6 signal
transduction, termed IL-6 trans-signaling. IL-6 trans-
signaling can transmit the IL-6 signal in the cells that
express only gp130 and promote an inflammatory re-
sponse through phosphorylation of Stat3. Because the
expression of gp130 is ubiquitous, there is a non-specific
enhancement of IL-6 trans-signaling is thought to be an
enhancer of canonical IL-6 signal pathway. The import-
ance of IL-6 trans-signaling in the etiology of several
chronic inflammations, such as asthma, colitis, and
rheumatoid arthritis, has been well documented [22–24].
We previously revealed that the activation of IL-6/Stat3
pathway via IL-6 trans-signaling plays a crucial role in
the development of ileitis in SAMP1/Yit mice and mur-
ine CAC models [25]. We induced CAC in BALB/c mice
by administering 9 cycles of treatment with 4–5 % DSS
in drinking water for 7 days and normal drinking water
for 7 days. CAC was microscopically observed in >60–
80 % of mice after DSS treatment. Histologically, we ob-
served the proliferation of gland epithelial cells, resulting
in the formation of a polypoid mass (Fig. 2a). Our hy-
pothesis of the association between IL-6 trans-signaling
and inflammation-based colon tumorigenesis is shown
in Fig. 1. IL-6 trans-signaling triggered in LP inputs its
downstream signal into intestinal epithelial cells (IECs)
and induces the expression of anti-apoptotic gene and
AID and the production of reactive oxygen species
(ROS), which leads to the inhibition of cell death, gen-
etic instability and DNA damage. Mice which are defi-
cient in both IL-10 and AID do not develop colon
cancer, whereas IL-10-deficient mice develop spontan-
eous colon cancers [26]. Aberrant AID expression in the
inflamed colonic mucosa plays an integral role during
the development of CAC via accumulation of genetic ab-
errations. Therefore it is speculated that long-term accu-
mulation of IL-6 trans-signaling finally leads to colon
tumorigenesis. Interestingly, the expression of IL-6,
TACE and phospho-Stat3 in CAC mucosa was higher
than those in the colitis mucosa (Fig. 2b). Soluble
gp130Fc (sgp130Fc) is a dimerized fusion protein of
gp130 that competitively suppresses the activation of IL-
6 trans-signaling by preventing the interaction between
gp130 and the IL-6/sIL-6Rα complex. Treatment of
DSS-induced CAC model with sgp130Fc suppressed the
expression of phospho-Stat3 and the incidence and
number of tumors were reduced, compared with
vehicle-treated mice (Fig. 2c). Consequently, it was
revealed that the activation of IL-6 trans-signaling in
colonic mucosa was essential for triggering CAC. In our
previous study, we indicated that the main source
supplying IL-6 in the development of CAC was
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macrophages and dendritic cells (DCs) located in colonic
lamina propria (LP). Moreover, it became clear that a
distinct subpopulation of LPDCs was the main sources
of sIL-6Rα. LP macrophages, purified from mice with
ongoing chronic colitis, actively cleaved sIL-6Rα into the
culture supernatant after stimulation with heat-killed
commensal bacteria ex vivo. However the presence of a
TACE inhibitor markedly reduced this cleavage. This
result indicates that gut microbiota participated in the
production of sIL-6Rα in colonic LP macrophage
through TACE activation. Interestingly, the expression of
membrane-bound IL-6Rα was markedly decreased in
epithelial cells of chronic colitis and CAC. In contrast,
the expression of gp130 was significantly increased in
epithelial cells of CAC. Therefore epithelial cells of
chronic colitis and CAC are thought to be in a state
more suitable for the receiving of IL-6 trans-signaling
than the canonical IL-6 signal pathway.
Probiotics as prevention for IBD/CAC
Reverting the disturbances of gut microbiota in patients
with IBD and CAC, as previously mentioned, should be-
come the new strategy for treatment. Although several
clinical trials using probiotics for patients with IBD have
been performed in Japan and overseas, the clinical
effects are dependent on the probiotic strain and the
schedule of probiotic administration. In the trial for the
patients with mildly to moderately active UC received
one of the probiotic Lactobacillus strains, Lactobacillus
casei strain Shirota (LcS), daily for 8 weeks, significantly
better clinical activity index scores were seen after LcS
treatment compared with pre-treatment and control
group values [27]. In the trial for people at high-risk of
developing colorectal cancer, they were administered
wheat bran, LcS, both or neither. Incidence of tumors
with a grade of moderate or high atypia was significantly
lower in the group administered LcS than the other
groups. No significant difference in the development of
new colorectal tumors was observed with administration
of either wheat bran or LcS [28]. After 1 year of treat-
ment with Bifidobacterium breve strain Yakult and
galacto-oligosaccharides symbiotics, the clinical status
was significantly improved, and the amount of myeloper-
oxidase in the lavage, the number of Bacteroidaceae in
feces and fecal pH was reduced in the patients with mild
to moderate UC [29]. We had reported previously that
LcS has the protective efficacy against CAC [30]. LcS
suppressed the development of CAC by suppressing
Fig. 1 Representative scheme of how IL-6 trans-signaling modulates inflammation-based colorectal tumorigenesis. Under inflammatory
conditions, sIL-6Rα is generated from LPDCs by TACE, which proteolytically cleaves the extracellular domain of membrane-bound IL-6Rα. Gut
microbiota had a key role on the activation of TACE. IL-6 is also produced by macrophages (Mϕs) and DCs in LP and binds to sIL-6Rα. The IL-6/
sIL-6Rα complex can associate with gp130 and induces IL-6 signal transduction through the phosphorylation of Stat3, termed IL-6 trans-signaling.
IL-6 trans-signaling triggered in LP inputs its downstream signal into intestinal epithelial cells (IECs) and induces the expression of anti-apoptotic
gene and AID and the production of reactive oxygen species (ROS), which leads to the inhibition of cell death, genetic instability and DNA
damage. It is speculated that long-term accumulation of IL-6 trans-signaling finally leads to colon tumorigenesis
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IL-6 trans-signaling in a murine CAC model, whereas
polysaccharide-peptidoglycan complex 1 (PS-PG1) defi-
cient LcS strain had no effect on the prevention of CAC
(Fig. 2d). It was also revealed that this effect of LcS was
accompanied with improvement of dysbiosis of gut
microbiota. As recently reported, transplant of fecal
microbiota from healthy individuals is effective in treat-
ment. However transplant of feces requires considered
attention in patients with benign disorders, such as IBD,
because there is a possibility of accidental contamination
with unknown infectious diseases. By avoiding this, pro-
biotics have guaranteed safeguards against such events.
Therefore amelioration of dysbiosis by using probiotics
could be a potent tool implemented as a new medical
treatment for these diseases as well as their prevention.
Conclusion
Gastrointestinal mucosa has a unique immune system, in
which many immune cells reside and exert multiple func-
tions. Those immune cells and gut microbiota have a mu-
tual influence on immune response. Recent studies
suggested that an imbalance of gut microbiota—“dysbiosi-
s”—is related to the condition of patients with not only
gastrointestinal diseases but also other diseases. It is esti-
mated that dysbiosis of gut microbiota plays an essential
role in the initiation of IBD and CAC. The strategy of re-
cent studies on IBD and CAC is altering, which aimed at
remedying dysbiosis by considering gut microbiota as “a
microbial community effect” from studies focused on indi-
vidual enterobacterial roles. Dysbiosis of gut microbiota
presumably induces the change in the enteric environ-
ment that leads to mucosal inflammation or tumorigen-
esis. It will be necessary to accumulate a scientific
overview for the interaction of gut microbiota and the
mucosal immune system in the future, to utilize the im-
provement of the gut microbiota as a mode of treatment
in the development of new cures for IBD and CAC.
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